Vanguard Group Inc. Has $55.30 Million Stock Position in Esperion Therapeutics, Inc. $ESPR

Posted by Francis Steltz on May 16th, 2026

Vanguard Group Inc. boosted its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 23.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,945,454 shares of the biopharmaceutical company’s stock after buying an additional 2,853,005 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Esperion Therapeutics worth $55,298,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics during the 2nd quarter worth approximately $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $29,000. R Squared Ltd acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $33,000. KFG Wealth Management LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $37,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Esperion Therapeutics by 49.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,617 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 3,822 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 target price on the stock. in a report on Friday, May 1st. Cantor Fitzgerald downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. Wall Street Zen upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 14th. Needham & Company LLC downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $5.54.

Read Our Latest Research Report on ESPR

Esperion Therapeutics Price Performance

NASDAQ ESPR opened at $3.12 on Friday. Esperion Therapeutics, Inc. has a 12-month low of $0.75 and a 12-month high of $4.18. The company has a market capitalization of $803.18 million, a PE ratio of -52.00, a price-to-earnings-growth ratio of 2.53 and a beta of 0.91. The firm’s 50 day moving average is $2.53 and its 200-day moving average is $3.10.

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.08). Esperion Therapeutics had a net margin of 0.12% and a negative return on equity of 0.14%. The business had revenue of $80.10 million during the quarter, compared to analyst estimates of $84.52 million. As a group, sell-side analysts expect that Esperion Therapeutics, Inc. will post 0.05 EPS for the current year.

Esperion Therapeutics Profile

(Free Report)

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.